Respinor: Difference between revisions
Created from Aleap incubator research |
Created with researched data |
||
| Line 1: | Line 1: | ||
{{ | {{DISPLAYTITLE:Respinor}} | ||
|name=Respinor | {{Infobox company | ||
| | | name = Respinor AS | ||
| | | org_number = 915417310 | ||
| | | founded = 2015-04-15 | ||
| | | employees = 9 | ||
| | | address = Norway | ||
| industry = 72.100 – Biotechnology research | |||
| website = https://respinor.com | |||
| nht_category = Startup | |||
| description = Respinor develops DXT — a novel non-invasive ultrasound-based medical device for accurate and continuous diaphragm monitoring. Enables early detection of diaphragm dysfunction in critical care settings. Successfully validated in clinical studies on mechanically ventilated patients. | |||
| notes = 9 employees. Successfully validated in clinical studies. Diaphragm dysfunction in ICU is a significant unmet need — affects ICU mortality and weaning outcomes. | |||
| related_companies = [[Cimon Medical]], [[ODI Medical]], [[GlucoSet]], [[Mode Sensors]], [[Norway Health Tech]] | |||
| categories = Norway Health Tech, Startups, Medical Devices, Intensive Care, Diagnostics, Respiratory | |||
| sources = https://respinor.com; https://data.brreg.no/enhetsregisteret/api/enheter/915417310 | |||
}} | }} | ||
== | == About == | ||
Respinor AS is a Norwegian medical technology company developing non-invasive ultrasound-based monitoring solutions for diaphragm function. Founded in 2015 with 9 employees. | |||
== | == Product == | ||
== | === DXT === | ||
[[Category: | DXT is a novel, non-invasive ultrasound device for diaphragm monitoring. Key features: | ||
[[Category: | |||
* Non-invasive ultrasound-based technology | |||
* Accurate and continuous diaphragm monitoring | |||
* Enables early detection of diaphragm dysfunction | |||
* Designed for critical care settings | |||
* Successfully validated in clinical studies on mechanically ventilated patients | |||
== Clinical Need == | |||
Diaphragm dysfunction in critically ill patients is associated with: | |||
* Increased mortality in ICU | |||
* Prolonged mechanical ventilation | |||
* Difficult weaning from ventilators | |||
* Increased healthcare costs | |||
Currently, monitoring diaphragm function in ICU patients is challenging. DXT addresses this with a non-invasive approach that can detect dysfunction early. | |||
== Market == | |||
Critical care monitoring represents a significant market. Diaphragm ultrasound is an emerging standard of care, and a dedicated device for continuous monitoring could address a growing clinical need as ICU awareness of diaphragm dysfunction increases. | |||
== References == | |||
<references/> | |||
[[Category:Norway Health Tech]] | |||
[[Category:Startups]] | |||
[[Category:Medical Devices]] | |||
[[Category:Intensive Care]] | |||
[[Category:Diagnostics]] | |||
[[Category:Respiratory]] | |||
Latest revision as of 20:32, 14 April 2026
About[edit]
Respinor AS is a Norwegian medical technology company developing non-invasive ultrasound-based monitoring solutions for diaphragm function. Founded in 2015 with 9 employees.
Product[edit]
DXT[edit]
DXT is a novel, non-invasive ultrasound device for diaphragm monitoring. Key features:
- Non-invasive ultrasound-based technology
- Accurate and continuous diaphragm monitoring
- Enables early detection of diaphragm dysfunction
- Designed for critical care settings
- Successfully validated in clinical studies on mechanically ventilated patients
Clinical Need[edit]
Diaphragm dysfunction in critically ill patients is associated with:
- Increased mortality in ICU
- Prolonged mechanical ventilation
- Difficult weaning from ventilators
- Increased healthcare costs
Currently, monitoring diaphragm function in ICU patients is challenging. DXT addresses this with a non-invasive approach that can detect dysfunction early.
Market[edit]
Critical care monitoring represents a significant market. Diaphragm ultrasound is an emerging standard of care, and a dedicated device for continuous monitoring could address a growing clinical need as ICU awareness of diaphragm dysfunction increases.